{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:22:23Z","timestamp":1784694143859,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Viatris, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40123-025-01118-x","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T06:40:05Z","timestamp":1742020805000},"page":"959-968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Varenicline Nasal Spray for the Treatment of Dry Eye Disease Following Corneal Collagen Crosslinking"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7754-0465","authenticated-orcid":false,"given":"Tanner J.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Durgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Whitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Swan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"issue":"6","key":"1118_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.survophthal.2015.04.002","volume":"60","author":"JB Randleman","year":"2015","unstructured":"Randleman JB, Khandelwal SS, Hafezi F. Corneal cross-linking. Surv Ophthalmol. 2015;60(6):509\u201323.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"1118_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jcrs.2019.06.027","volume":"45","author":"KA Beckman","year":"2019","unstructured":"Beckman KA, Gupta PK, Farid M, et al. Corneal crosslinking: current protocols and clinical approach. J Cataract Refract Surg. 2019;45(11):1670\u20139. https:\/\/doi.org\/10.1016\/j.jcrs.2019.06.027.","journal-title":"J Cataract Refract Surg"},{"issue":"9","key":"1118_CR3","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/S0886-3350(03)00407-3","volume":"29","author":"G Wollensak","year":"2003","unstructured":"Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of human and porcine corneas after riboflavin\u2013ultraviolet-A-induced cross-linking. J Cataract Refract Surg. 2003;29(9):1780\u20135.","journal-title":"J Cataract Refract Surg"},{"issue":"1","key":"1118_CR4","first-page":"13","volume":"91","author":"AY Yang","year":"2018","unstructured":"Yang AY, Chow J, Liu J. Focus: sensory biology and pain: corneal innervation and sensation: the eye and beyond. Yale J Biol Med. 2018;91(1):13.","journal-title":"Yale J Biol Med"},{"issue":"2","key":"1118_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/IIO.0000000000000104","volume":"56","author":"TH Dohlman","year":"2016","unstructured":"Dohlman TH, Lai EC, Ciralsky JB. Dry eye disease after refractive surgery. Int Ophthalmol Clin. 2016;56(2):101\u201310. https:\/\/doi.org\/10.1097\/IIO.0000000000000104.","journal-title":"Int Ophthalmol Clin"},{"issue":"3","key":"1118_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/ICU.0000000000000569","volume":"30","author":"EC O\u2019Neil","year":"2019","unstructured":"O\u2019Neil EC, Henderson M, Massaro-Giordano M, Bunya VY. Advances in dry eye disease treatment. Curr Opin Ophthalmol. 2019;30(3):166.","journal-title":"Curr Opin Ophthalmol"},{"key":"1118_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-024-00976-1","author":"CA Blackie","year":"2024","unstructured":"Blackie CA, Murakami D, Donnenfeld E, Oliff HS. Vectored thermal pulsation as a treatment for meibomian gland dysfunction: a review spanning 15 years. Ophthalmol Ther. 2024. https:\/\/doi.org\/10.1007\/s40123-024-00976-1. (Published online June 15, 2024).","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"1118_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/ICO.0000000000002837","volume":"41","author":"PK Gupta","year":"2022","unstructured":"Gupta PK, Holland EJ, Hovanesian J, et al. TearCare for the treatment of Meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea. 2022;41(4):417\u201326. https:\/\/doi.org\/10.1097\/ICO.0000000000002837.","journal-title":"Cornea"},{"issue":"1","key":"1118_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jtos.2018.11.002","volume":"17","author":"G Dieckmann","year":"2019","unstructured":"Dieckmann G, Fregni F, Hamrah P. Neurostimulation in dry eye disease\u2014past, present, and future. Ocul Surf. 2019;17(1):20\u20137.","journal-title":"Ocul Surf"},{"issue":"3","key":"1118_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/IJG.0b013e31820bd2e1","volume":"21","author":"R Gupta","year":"2012","unstructured":"Gupta R, Patil B, Shah BM, Bali SJ, Mishra SK, Dada T. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma. 2012;21(3):189\u201392. https:\/\/doi.org\/10.1097\/IJG.0b013e31820bd2e1.","journal-title":"J Glaucoma"},{"issue":"4","key":"1118_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","volume":"129","author":"D Wirta","year":"2022","unstructured":"Wirta D, Vollmer P, Paauw J, et al. Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial. Ophthalmology. 2022;129(4):379\u201387. https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.004.","journal-title":"Ophthalmology"},{"key":"1118_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","volume":"24","author":"H Quiroz-Mercado","year":"2022","unstructured":"Quiroz-Mercado H, Hernandez-Quintela E, Chiu KH, Henry E, Nau JA. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study. Ocul Surf. 2022;24:15\u201321. https:\/\/doi.org\/10.1016\/j.jtos.2021.12.007.","journal-title":"Ocul Surf"},{"issue":"10","key":"1118_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","volume":"41","author":"D Wirta","year":"2022","unstructured":"Wirta D, Torkildsen GL, Boehmer B, et al. ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease. Cornea. 2022;41(10):1207\u201316. https:\/\/doi.org\/10.1097\/ICO.0000000000002941.","journal-title":"Cornea"},{"issue":"4","key":"1118_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/ICU.0b013e3283009ef8","volume":"19","author":"GG Quinto","year":"2008","unstructured":"Quinto GG, Camacho W, Behrens A. Postrefractive surgery dry eye. Curr Opin Ophthalmol. 2008;19(4):335\u201341.","journal-title":"Curr Opin Ophthalmol"},{"key":"1118_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.5935\/0004-2749.20180100","volume":"81","author":"D Ozek","year":"2018","unstructured":"Ozek D, Kemer OE. Effect of the bioprotectant agent trehalose on corneal epithelial healing after corneal cross-linking for keratoconus. Arq Bras Oftalmol. 2018;81:505\u20139.","journal-title":"Arq Bras Oftalmol"},{"issue":"4","key":"1118_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/OPX.0000000000001500","volume":"97","author":"A Kirgiz","year":"2020","unstructured":"Kirgiz A, Akdemir MO, Yilmaz A, Kaldirim H, Atalay K, Asik NS. The use of autologous serum eye drops after epithelium-off corneal collagen crosslinking. Optom Vis Sci. 2020;97(4):300\u20134. https:\/\/doi.org\/10.1097\/OPX.0000000000001500.","journal-title":"Optom Vis Sci"},{"issue":"10","key":"1118_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/jamaophthalmol.2016.3019","volume":"134","author":"AM Bata","year":"2016","unstructured":"Bata AM, Witkowska KJ, Wozniak PA, et al. Effect of a matrix therapy agent on corneal epithelial healing after standard collagen cross-linking in patients with keratoconus: a randomized clinical trial. JAMA Ophthalmol. 2016;134(10):1169\u201376. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.3019.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1118_CR18","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s40123-024-00949-4","volume":"13","author":"TJ Ferguson","year":"2024","unstructured":"Ferguson TJ, Messer B, Risbrudt N, Stofferahn S, Greenwood M. Varenicline solution nasal spray for the treatment of dry eye disease following LASIK. Ophthalmol Ther. 2024;13(6):1693\u2013701 (Published online 2024).","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"1118_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/OPX.0000000000001986","volume":"100","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, O\u2019Dell LE, Karpecki PM, et al. Does dry eye disease severity impact efficacy of varenicline solution nasal spray on sign and symptom treatment outcomes? Optom Vis Sci. 2023;100(2):164\u20139. https:\/\/doi.org\/10.1097\/OPX.0000000000001986.","journal-title":"Optom Vis Sci"},{"key":"1118_CR20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/08820538.2015.1009554","volume":"31","author":"A Abbouda","year":"2016","unstructured":"Abbouda A, Abicca I, Alio J. Infectious keratitis following corneal crosslinking: a systematic review of reported cases: management, visual outcome, and treatment proposed. Seminars Ophthalmol. 2016;31:485\u201391.","journal-title":"Seminars Ophthalmol"},{"issue":"7","key":"1118_CR21","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.18240\/ijo.2018.07.04","volume":"11","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Lu XY, Hu RJ, Fan FL, Jin XM. Evaluation of artificial tears on cornea epithelium healing. Int J Ophthalmol. 2018;11(7):1096\u2013101. https:\/\/doi.org\/10.18240\/ijo.2018.07.04.","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"1118_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaophthalmol.2023.1109","volume":"141","author":"MK Shoji","year":"2023","unstructured":"Shoji MK, Gutkind NE, Meyer BI, et al. Multidrug-resistant Pseudomonas aeruginosa keratitis associated with artificial tear use. JAMA Ophthalmol. 2023;141(5):499\u2013500. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.1109.","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01118-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:41:25Z","timestamp":1744893685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01118-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01118-x","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Russell J. Swan, MD, reports research funding from Viatris, Inc. Tanner J. Ferguson, MD, has no relevant financial disclosures. Travis Whitt, OD, has no relevant financial disclosures. David Durgan has no relevant financial disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was reviewed and approved by the Western Institutional Review Board (WCG). All procedures conducted were in accordance with the WCG IRB and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained for each subject prior to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}